MedPath

Effect Of Tranexamic acid By Microneedling in Melasma.

Phase 3
Conditions
Melasma..
Registration Number
IRCT20180811040761N1
Lead Sponsor
Kerman University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
30
Inclusion Criteria

All Women with Melasma.

Exclusion Criteria

Coagulopathy Disease.
Hormone Therapy.
Topical treatment, like Hydroquinone, in the past year.
Active Herpes.
Facial Wart.
Hypersensivity to Tranexamic acid & Hydroquinone.
Pregnancy and Lactation.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Melasma intensity based on MASI (Melasma Area Severity Index ) score. Timepoint: (Melasma Area Severity Index ) MASI Score measurement at the beginning of the study and weeks 4, 8,12. Method of measurement: Using the Melasma Area Severity Index (MASI) Score.;The rate of recovery of melasma lesions based on the Patient Global Assessment. Timepoint: The rate of improvement of melasma lesions at the end of the study was based on the Patient Global Assessment questionnaire. Method of measurement: Patient Global Assessment Questionnaire.;The rate of recovery of melasma lesions based on the Patient Global Assessment. Timepoint: The rate of improvement of melasma lesions at the end of the study was based on the Physician Global Assessment questionnaire. Method of measurement: Physician Global Assessment Questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath